^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | KB-0742 (CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2639 / 8 - KB-0742 is active in preclinical MYC high models of TNBC, ovarian, and DLBCL cancers
Published date:
03/09/2022
Excerpt:
To better understand the connection between MYC and KB-0742 sensitivity, 11 different tumor types were evaluated preclinically...The 11 indications included head and neck, esophageal, gastric, liver, non-small cell lung cancer (NSCLC), pancreatic, ovarian, triple-negative breast cancer (TNBC), prostate, colon, and lymphoma. However, in vivo assessments using 15 PDX models showed good correlation of tumor growth inhibition (TGI) and MYC amplification/expression, with some tumor regressions observed in several ovarian models.
